Skip to Main Content

Amid a growing number of probes into drug makers and patient charities, Pfizer (PFE) has agreed to pay nearly $23.8 million to resolve charges of illegally using a supposedly independent charity to pay kickbacks to Medicare patients as a way to cover their out-of-pocket costs.

Specifically, the Department of Justice alleged that Pfizer used the Patient Access Network Foundation as a conduit to cover co-pay costs for Medicare patients taking three of its drugs, according to the settlement agreement. These drugs were Sutent and Inlyta, which both treat renal cell carcinoma, and Tikosyn, which treats arrhythmia in patients with atrial fibrillation or atrial flutter.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!